Clin2
NCT06271200Possibly a fitRecruiting

Lifestyle change and medication for metabolic syndrome

Metabolic Syndrome

Part of Hormones & metabolism clinical trials.

This trial tests a lifestyle program combined with two medications (semaglutide and dapagliflozin) to help people with metabolic syndrome lose weight and improve their health. It may be an option if you are an adult with a BMI of 27 to 45 and have metabolic syndrome.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
200 people
Ages
20 years to 65 years
Study type
Interventional

Who can take part

  • You are between 20 and 65 years old
  • Your body mass index (BMI) is between 27 and 45
  • You have been told you have metabolic syndrome (a cluster of conditions like high blood sugar, high blood pressure, or unhealthy cholesterol)
  • You do not have type 1 or type 2 diabetes that requires medication
  • You are not currently taking weight-loss drugs or participating in a weight-loss program
  • You can commit to the study for 3 years

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06410352Recruiting· Phase 4
Weight loss methods for longer life with metabolic syndrome

This trial tests weight loss methods in people with type 2 diabetes, high blood pressure, and excess weight. It aims to see if losing 15-20% of body weight can help people live longer and healthier.

Astana, Astana
NCT07065357Enrolling by invitation· Phase 3
A study on a diabetes drug for metabolic syndrome

This trial tests if empagliflozin, a medication typically used for diabetes, can help people with metabolic syndrome (a cluster of conditions like large waist size, high blood sugar, and high blood pressure). It may improve health and reduce the risk of heart disease.

Hong Kong
NCT07770282Not yet recruiting· Phase 3
Semaglutide for heart health in schizophrenia with metabolic syndrome

This trial tests whether semaglutide, a drug used for diabetes and weight loss, can improve heart-related health in people with schizophrenia who also have metabolic syndrome (a cluster of conditions like high blood pressure, high blood sugar, and excess belly fat). If it works, it could lower the risk of heart disease and stroke.

NCT04990024Recruiting
Diet trial for people with obesity using semaglutide

This study compares different diets to see how they affect “arterial stiffness” (how hard the blood vessels are) in people with obesity who are starting semaglutide for weight management. It may help find a diet approach that improves heart and blood-vessel health while you use semaglutide.

Beirut, Riad El Solh
NCT07323134Not yet recruiting
Semaglutide for obesity and gut health

This study tests if a medication called semaglutide can help people with obesity lose weight by changing the bacteria in their gut. You may be able to join if you have obesity, have tried to lose weight before, and are generally healthy.

NCT06762314Recruiting· Phase 2
Empagliflozin or semaglutide for overweight people with type 1 diabetes

This study tests two different medicines (empagliflozin or semaglutide) added to your usual insulin to see if they help with blood sugar control and weight loss in people with type 1 diabetes who are overweight or have obesity. It may be a good fit if your diabetes is not well controlled with insulin injections alone.

Tanta

Hear when a new Metabolic Syndrome trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.